The use of immunotropic therapy for the combination treatment of patients with chronic bacterial cystitis

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. Treatment of lower urinary tract infection primarily involves the antibiotics. However, the efficiency of antibacterial therapy has significantly decreased. Immunomodulators are recognized as the most important link in the pathogenetic therapy of chronic cystitis, which can prevent the development of chronic inflammation. In recent years, a number of publications have appeared proving the benefits of immunomodulatory therapy.

Aim. To carry out a comparative analysis of the efficiency of various dosages of the drug VIFERON® for the combination treatment of chronic recurrent bacterial cystitis.

Materials and methods. A total of 90 women aged from 18 to 45 years with chronic bacterial cystitis in the acute stage were included in the study. They were divided into 3 groups of 30 each. In group 1, women received antibacterial therapy. In group 2, the drug VIFERON® was prescribed in the form of suppositories of 1,000,000 IU rectally for 10 days in combination with antibacterial therapy. In group 3, standard antibacterial therapy was prescribed with VIFERON® b at 3,000,000 IU rectally for 10 days. The follow-up was carried out on the 1st, 5th and 10th days.

Results. On the 1st day in both groups there were signs of exacerbation of chronic cystitis, such as frequent urination, burning during urination, urgency, nocturia, leukocyturia. The results of clinical and laboratory studies obtained on the 5th day of therapy in groups 2 and 3 differed significantly (p<0.05) from those in group 1. In addition, the number of episodes of nocturia and urgency per day, and the pain intensity were closer to normal in group 3. These differences were also significant (p<0.05). By the 10th day of therapy, the average values of the clinical and laboratory parameters decreased to normal levels in all three groups; there were no significant differences (p<0.05). Despite the fact that at baseline bacterial nature of the cystitis was confirmed in all patients, by the 5th day of therapy, eradication of the pathogen was registered in all cases.

Conclusion. A combination of immunomodulators and antibiotics results in a rapid significant improvement in women with chronic bacterial cystitis by the 5th day of therapy. The use of the drug VIFERON® at a dose of 3,000,000 IU in combination with antibacterial therapy demonstrated the greatest efficiency in clinical and laboratory manifestations.

Full Text

Restricted Access

About the authors

A. V. Kuzmenko

FGBOU VO «Voronezh State Medical University named after N.N. Burdenko»

Email: kuzmenkoav09@yandex.ru
ORCID iD: 0000-0002-7927-7015

Ph.D., MD, professor, professor at the Department of Specialized Surgical disciplines

Russian Federation, Voronezh

T. A. Gyaurgiev

FGBOU VO «Voronezh State Medical University named after N.N. Burdenko»

Email: gta001100@yandex.ru
ORCID iD: 0000-0002-2209-6264

Ph.D., MD, professor, professor at the Department of Specialized Surgical disciplines

Russian Federation, Voronezh

G. A. Kuzmenko

FGBOU VO «Voronezh State Medical University named after N.N. Burdenko»

Email: KGA00110009@yandex.ru
ORCID iD: 0000-0002-6308-5211

2-year student of the Pediatric faculty

Russian Federation, Voronezh

T. S. Guseva

N.F. Gamaleya Research Сеnter for Epidemiology and Microbiology, Ministry of Health of the Russian Federation

Author for correspondence.
Email: oparcae@mail.ru
ORCID iD: 0000-0003-3163-4519

researcher of the Laboratory of ontogenesis and correction of interferon system

Russian Federation, Moscow

References

  1. Russian clinical guidelines «Cystitis in women» (2021) (Российские клинические рекомендации «Цистит у женщин» (2021).
  2. EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2022. ISBN 978-94-92671-16-5.
  3. Anger J., Lee U., Ackerman A.L. et. al. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. J Urol. 2019;202(2):282–289. doi: 10.1097/JU.0000000000000296. Epub 2019 Jul 8
  4. Sinyakova L.A. Modern views on antibacterial therapy of the urinary tract. Tactics of management of patients with recurrent cystitis. Urologiia. 2010;3:45–49. Russian (Синякова Л.А. Современные взгляды на антибактериальную терапию мочевыводящих путей. Тактика ведения больных с рецидивирующим циститом. Урология. 2010;3:45–49).
  5. Gadzhieva Z.K., Kazilov Y.B. Features of the approach to prevention of recurrent infections of the lower urinary tract. Urologiia. 2016;S3:65–76. Russian (Гаджиева З.К., Казилов Ю.Б. Особенности подхода к профилактике рецидивирующей инфекции нижних мочевыводящих путей. Урология. 2016(S3):65–76).
  6. Kuzmenko A.V., Kuzmenko V.V., Gyaurgiev T.A. Chronobiological approach to the treatment of chronic recurrent bacterial cystitis in the acute stage. Urologiia. 2017;2:60–65. Russian (Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А. Хронобиологический подход к терапии хронического рецидивирующего бактериального цистита в стадии обострения. Урология. 2017;2:60–65).
  7. Kuzmenko A.V., Kuzmenko V.V., Gyaurgiev T.A. Current trends in the treatment of chronic recurrent bacterial cystitis. Urologiia. 2020;6: 52–57. Russian (Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А. Современные тенденции в лечении хронического рецидивирующего бактериального цистита. Урология. 2020;6: 52–57).
  8. Kuzmenko A.V., Kuzmenko V.V., Gyaurgiev T.A. The use of D-mannose in the prevention of recurrent lower urinary tract infection in women. Urologiia. 2020;3:128-132. Russian (Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А. Применение D-маннозы в профилактике рецидивирующей инфекции нижних мочевыводящих путей у женщин. Урология. 2020;3:128-132).
  9. Ny S., Edquist P., Dumpis U., Grondahl-Yli-Hannuksela K. et al. Antibiotic resistance of Escherichia coli from outpatient urinary tract infection in women in six European countries including Russia. Journal of Global Antimicrobial Resistance. 2019;17:25–34. doi: 10.1016/j.jgar.2018.11.004.
  10. Palagin I. S., Sukhorukova M. V., Dekhnich A.V., eidelstein M. V., Shevelev A. N., Grinev A.V., Perepanova T. S., Kozlov R. S., research group DARMIS. The current state of antibiotic resistance of pathogens of community-acquired urinary tract infections in Russia: results of the study «DARMIS» (2010–2011). Clinical Microbiology and antimicrobial chemotherapy. 2012;14(4):280–302. Russian (Палагин И.С., Сухорукова М.В., Дехнич А.В., Эйдельштейн М.В., Шевелев А.Н., Гринев А.В., Перепанова Т.С., Козлов Р.С., исследовательская группа ДАРМИС. Современное состояние антибиотикорезистентности возбудителей внебольничных инфекций мочевых путей в России: результаты исследования ДАРМИС (2010–2011). Клиническая микробиология и антимикробная химиотерапия. 2012;14(4):280–302).
  11. Palagin I.S., Sukhorukova M.V., Dekhnich A.V., Eydel’shteyn M.V., Perepanova T.S., Kozlov R.S. Antibiotic resistance of nonhospital urinary tract pathogens in Russia: results of the DARMIS-2018 multicenter study. Clinical Microbiology and Antimicrobial Chemotherapy, 2019;21(2):134–46. doi: 10.36488/cmac.2019.2.134-146 Russian (Палагин И.С., Сухорукова М.В., Дехнич А.В., и др. Антибиотикорезистентность возбудителей внебольничных инфекций мочевых путей в России: результаты многоцентрового исследования «ДАРМИС-2018». Клиническая микробиология и антимикробная химиотерапия. 2019;21(2):134–46).
  12. Shepherd A.K., Pottinger P.S. Management of Urinary Tract Infections in the Era of Increasing Antimicrobial Resistance. Med Clin N Am. 2013;97:737–757.
  13. Strategy to Prevent the Spread of Antimicrobial Resistance in the Russian Federation until 2030. URL: https://www.garant.ru/products/ ipo/prime/doc/71677266 Russian (Стратегия предупреждения распространения антимикробной резистентности в Российской Федерации на период до 2030 года [Электронный ресурс]: утв. распоряжением Правительства Российской Федерации от 25 сент. 2017 г. № 2045-р // ГАРАНТ.РУ. Инф.-правовой портал.)
  14. Naboka Yu.L., Gudima I.A., Miroshnichenko E.A., Kogan M.I., Ibishev H.S., Vasilyeva L.I. Etiological structure and antibiotic sensitivity of uropathogens in chronic recurrent lower urinary tract infection. Urologiia. 2011; 6:12–16. Russian (Набока Ю. Л., Гудима И.А., Мирошничнко Е.А., Коган М.И., Ибишев Х.С., Васильева Л.И. Этиологическая структура и антибиотикочувствительность уропатогенов при хронической рецидивирующей инфекции нижних мочевых путей. Урология. 2011;6:12–16).
  15. Kuzmenko A.V., Kuzmenko V.V., Gyaurgiev T.A. Systemic enzyme therapy in the treatment of women with chronic recurrent bacterial cystitis. Urologia. 2020;2:35-40. Russian (Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А. Системная энзимотерапия в лечении женщин с хроническим рецидивирующим бактериальным циститом. Урология. 2020;2:35-40).
  16. Kuzmenko A.V., Gyaurgiev T.A., Kuzmenko V.V. Efficacy of fosfomycin trometamol for acute uncomplicated cystitis. Urologiia. 2018;6:70–75. Russian (Кузьменко А.В., Гяургиев Т.А., Кузьменко В.В. Эффективность применения фосфомицина трометамола при остром неосложненном цистите. Урология. 2018;6:70–75).
  17. Ibishev H. S. The expediency of interferon therapy for recurrent lower urinary tract infection. The Attending Physician. 2013;12:88–91. Russian (Ибишев Х.С. Целесообразность интерферонотерапии при рецидивирующей инфекции нижних мочевых путей. Лечащий Врач. 2013;12:88–91).
  18. Ibishev H.S., Malinovskaya V.V., Parfenov V.V. Treatment of persistent infection of the lower urinary tract in women. The Attending Physician. 2014;9:90–93. Russian (Ибишев Х.С., Малиновская В.В., Парфенов В.В. Лечение персистирующей инфекции нижних мочевых путей у женщин. Лечащий Врач. 2014;9:90–93).
  19. https: grls.rosminzdrav.ru
  20. Instructions for medical use of Viferon Russian (Инструкция по медицинскому применению препарата ВИФЕРОН®).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Figure. Spectrum of pathogens in three groups on the 1st day of therapy

Download (207KB)
Indexing metadata

Copyright (c) 2023 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies